In chronic kidney disease care, the central clinical question is often not the exact glomerular filtration rate (GFR) at a ...

Please provide your email address to receive an email when new articles are posted on . Patients with an eGFR below the 25th percentile of distribution for their age and sex had greater risks for ...

Please provide your email address to receive an email when new articles are posted on . The paper provides a race-free equation to estimate kidney filtration in adults with stable kidney function. It ...

Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...

Hello. It's Mark Kris, from Memorial Sloan Kettering. I'm about to say some things that will not make everyone happy. I would like to comment on a recently published article in The New England Journal ...

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut disease progression risk for EGFR-positive non–small cell lung cancer (NSCLC).

The identification of all potential EGFR driver mutations is especially critical for patients with lung adenocarcinoma from East Asia or of Asian descent because of the prevalence of such mutations ...